The DOI matches its Crossref record; 202 of the 202 references it cites were found in a registry or an index.
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Open accessAbstract
Mitogen-activated protein kinase (MAPK) pathways represent ubiquitous signal transduction pathways that regulate all aspects of life and are frequently altered in disease. Here, we focus on the role of MAPK pathways in modulating drug sensitivity and resistance in cancer. We briefly discuss new findings in the extracellular signaling-regulated kinase (ERK) pathway, but mainly focus on the mechanisms how stress activated MAPK pathways, such as p38 MAPK and the Jun N-terminal kinases (JNK), impact the response of cancer cells to chemotherapies and targeted therapies. In this context, we also discuss the role of metabolic and epigenetic aberrations and new therapeutic opportunities arising from these changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sui, X., Kong, N., Wang, X., Fang, Y., Hu, X., Xu, Y., Chen, W., Wang, K., Li, D., Jin, W., et al. (2014) · Scientific Reports · doi:10.1038/srep04694 · Cited by 115
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis
Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., & Greenberg, M. E. (1995) · Science · doi:10.1126/science.270.5240.1326 · Cited by 5,287
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“Gefitinib Selective EGFR inhibitor (ATP competitive) EGFR T790M mutation [32,33]; Gene amplification (e.”
BackgroundActivation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“This is associated with glycolysis as the glycolytic pathway supplies the energy and fuel required for FA synthesis [165].”
BackgroundA decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Mechanisms and functions of p38 MAPK signalling
Cuadrado, A., & Nebreda, A. R. (2010) · Biochemical Journal · doi:10.1042/bj20100323 · Cited by 1,676
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 2×
“Vemurafenib Selective BRAF V600E inhibitor (ATP competitive) Activating mutations in NRAS or MEK [23,24]; BRAF/CRAF amplification [23,25]; BRAF alternative splicing [26,27]; RAF heterodimerization [28]; RTK upregulation [29]; Loss of NF1 [30]; COT upregulation [31] Dabrafenib”
BackgroundEpigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
You, J. S., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.008 · Cited by 1,167
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915 · cited 1×
“Overall, both genetic and epigenetic factors contribute to the development of phenotypically distinct tumor cell clones and intratumoral heterogeneity [168,178,179].”
BackgroundGlucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K. V., Markowitz, S., Zhou, S., et al. (2009) · Science · doi:10.1126/science.1174229 · Cited by 914
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
Feinberg, A. P., Koldobskiy, M. A., & Göndör, A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.13 · Cited by 841
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Smeal, T., Binetruy, B., Mercola, D. A., Birrer, M., & Karin, M. (1991) · Nature · doi:10.1038/354494a0 · Cited by 789
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771
Vazquez, F., Lim, J.-H., Chim, H., Bhalla, K., Girnun, G., Pierce, K., Clish, C. B., Granter, S. R., Widlund, H. R., Spiegelman, B. M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.020 · Cited by 715
Epigenetic reprogramming in cancer
Suvà, M. L., Riggi, N., & Bernstein, B. E. (2013) · Science · doi:10.1126/science.1230184 · Cited by 706
Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.003 · Cited by 670 · cited 1×
“Roesch and colleagues identified another intrinsic resistance mechanism in BRAF V600E mediated malignant melanoma mediated by altered histone modifications [192].”
BackgroundSuraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585
Yao, Z., Torres, N. M., Tao, A., Gao, Y., Luo, L., Li, Q., de Stanchina, E., Abdel-Wahab, O., Solit, D. B., Poulikakos, P. I., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.001 · Cited by 543
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset
Ceol, C. J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D. A., Battisti, V., Fritsch, L., Lin, W. M., Hollmann, T. J., Ferré, F., et al. (2011) · Nature · doi:10.1038/nature09806 · Cited by 542
JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships
Zeke, A., Misheva, M., Reményi, A., & Bogoyevitch, M. A. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00043-14 · Cited by 523
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508
Massarweh, S., Osborne, C. K., Creighton, C. J., Qin, L., Tsimelzon, A., Huang, S., Weiss, H., Rimawi, M., & Schiff, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2707 · Cited by 488
Cancer epigenetics: Moving forward
Nebbioso, A., Tambaro, F. P., Dell’Aversana, C., & Altucci, L. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007362 · Cited by 480
Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478 · cited 1×
“Vemurafenib Selective BRAF V600E inhibitor (ATP competitive) Activating mutations in NRAS or MEK [23,24]; BRAF/CRAF amplification [23,25]; BRAF alternative splicing [26,27]; RAF heterodimerization [28]; RTK upregulation [29]; Loss of NF1 [30]; COT upregulation [31] Dabrafenib”
BackgroundGarrett, J. T., Olivares, M. G., Rinehart, C., Granja-Ingram, N. D., Sánchez, V., Chakrabarty, A., Dave, B., Cook, R. S., Pao, W., McKinely, E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016140108 · Cited by 467
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 445
Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours
Garcia-Bermudez, J., Baudrier, L., La, K., Zhu, X. G., Fidelin, J., Sviderskiy, V. O., Papagiannakopoulos, T., Molina, H., Snuderl, M., Lewis, C. A., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0118-z · Cited by 442
Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y.-L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203530109 · Cited by 441
The complexity of mitogen-activated protein kinases (MAPKs) made simple
Krishna, M., & Narang, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8170-7 · Cited by 432
New perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
p38α MAP Kinase as a Sensor of Reactive Oxygen Species in Tumorigenesis
Dolado, I., Swat, A., Ajenjo, N., De Vita, G., Cuadrado, A., & Nebreda, A. R. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.013 · Cited by 404
Raf Family Kinases: Old Dogs Have Learned New Tricks
Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., & Kolch, W. (2011) · Genes & Cancer · doi:10.1177/1947601911407323 · Cited by 386
Self-citationWang, W., Chen, J. X., Liao, R., Deng, Q., Zhou, J. J., Huang, S., & Sun, P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3389-3403.2002 · Cited by 376
Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375 · cited 1×
“Vemurafenib Selective BRAF V600E inhibitor (ATP competitive) Activating mutations in NRAS or MEK [23,24]; BRAF/CRAF amplification [23,25]; BRAF alternative splicing [26,27]; RAF heterodimerization [28]; RTK upregulation [29]; Loss of NF1 [30]; COT upregulation [31] Dabrafenib”
BackgroundA Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Whittaker, S. R., Theurillat, J.-P., Van Allen, E., Wagle, N., Hsiao, J., Cowley, G. S., Schadendorf, D., Root, D. E., & Garraway, L. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0470 · Cited by 359
JNK-signaling: A multiplexing hub in programmed cell death
Dhanasekaran, D. N., & Reddy, E. P. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.155 · Cited by 358
p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway
Hui, L., Bakiri, L., Mairhorfer, A., Schweifer, N., Haslinger, C., Kenner, L., Komnenovic, V., Scheuch, H., Beug, H., & Wagner, E. F. (2007) · Nature Genetics · doi:10.1038/ng2033 · Cited by 352
JNK signalling in cancer: in need of new, smarter therapeutic targets
Bubici, C., & Papa, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12432 · Cited by 346
The dynamic control of signal transduction networks in cancer cells
Kolch, W., Halasz, M., Granovskaya, M., & Kholodenko, B. N. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3983 · Cited by 339
Self-citationAn Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Wang, L., Leite de Oliveira, R., Huijberts, S., Bosdriesz, E., Pencheva, N., Brunen, D., Bosma, A., Song, J.-Y., Zevenhoven, J., Los-de Vries, G. T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.012 · Cited by 327
Johnson, D. B., Menzies, A. M., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Rizos, H., Sucker, A., Scolyer, R. A., Gutzmer, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.022 · Cited by 323
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., & Rosen, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609973103 · Cited by 308
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Hui, L., Zatloukal, K., Scheuch, H., Stepniak, E., & Wagner, E. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37156 · Cited by 307
Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4
Zanconato, F., Battilana, G., Forcato, M., Filippi, L., Azzolin, L., Manfrin, A., Quaranta, E., Di Biagio, D., Sigismondo, G., Guzzardo, V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0158-8 · Cited by 306
Poised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301 · cited 1×
“Overall, both genetic and epigenetic factors contribute to the development of phenotypically distinct tumor cell clones and intratumoral heterogeneity [168,178,179].”
BackgroundParmenter, T. J., Kleinschmidt, M., Kinross, K. M., Bond, S. T., Li, J., Kaadige, M. R., Rao, A., Sheppard, K. E., Hugo, W., Pupo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0440 · Cited by 283
Kakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182721 · Cited by 277
Tumour-specific proline vulnerability uncovered by differential ribosome codon reading
Loayza-Puch, F., Rooijers, K., Buil, L. C. M., Zijlstra, J., F. Oude Vrielink, J., Lopes, R., Ugalde, A. P., van Breugel, P., Hofland, I., Wesseling, J., et al. (2016) · Nature · doi:10.1038/nature16982 · Cited by 272
The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier
Sturm, O. E., Orton, R., Grindlay, J., Birtwistle, M., Vyshemirsky, V., Gilbert, D., Calder, M., Pitt, A., Kholodenko, B., & Kolch, W. (2010) · Science Signaling · doi:10.1126/scisignal.2001212 · Cited by 247
Self-citationOncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils
Torti, D., & Trusolino, L. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100176 · Cited by 246
Targeting Epigenetics in Cancer
Bennett, R. L., & Licht, J. D. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105106 · Cited by 246
ONECUT2 is a driver of neuroendocrine prostate cancer
Guo, H., Ci, X., Ahmed, M., Hua, J. T., Soares, F., Lin, D., Puca, L., Vosoughi, A., Xue, H., Li, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08133-6 · Cited by 243
The Warburg effect: Evolving interpretations of an established concept
Chen, X., Qian, Y., & Wu, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.08.027 · Cited by 229
Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer
Guo, H., Ahmed, M., Zhang, F., Yao, C. Q., Li, S., Liang, Y., Hua, J., Soares, F., Sun, Y., Langstein, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3637 · Cited by 226
Natural course and biology of CML
Chereda, B., & Melo, J. V. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2325-z · Cited by 220
Feng, W. W., Wilkins, O., Bang, S., Ung, M., Li, J., An, J., del Genio, C., Canfield, K., DiRenzo, J., Wells, W., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.008 · Cited by 216
p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance
Grossi, V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9744 · Cited by 214
Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice.
Chen, N., Nomura, M., She, Q., Ma, W. Y., Bode, A. M., Wang, L. Q., Flavell, R. A., & Dong, Z. (2001) · PubMed · Cited by 213
Epigenetic mechanisms as a new approach in cancer treatment: An updated review
Fardi, M., Solali, S., & Farshdousti Hagh, M. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.06.003 · Cited by 209
Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
de Bruin, E. C., Cowell, C., Warne, P. H., Jiang, M., Saunders, R. E., Melnick, M. A., Gettinger, S., Walther, Z., Wurtz, A., Heynen, G. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0741 · Cited by 203
JNK Pathway Signaling: A Novel and Smarter Therapeutic Target for Various Biological Diseases
Kumar, A., Singh, U. K., Kini, S. G., Garg, V., Agrawal, S., Tomar, P. K., Pathak, P., Chaudhary, A., Gupta, P., & Malik, A. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.132 · Cited by 200
Yao, Z., Gao, Y., Su, W., Yaeger, R., Tao, J., Na, N., Zhang, Y., Zhang, C., Rymar, A., Tao, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0274-5 · Cited by 195
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
Luebker, S. A., & Koepsell, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00268 · Cited by 194
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis
Rotinen, M., You, S., Yang, J., Coetzee, S. G., Reis-Sobreiro, M., Huang, W.-C., Huang, F., Pan, X., Yáñez, A., Hazelett, D. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0241-1 · Cited by 191
The Stress Kinase p38α as a Target for Cancer Therapy
Igea, A., & Nebreda, A. R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0173 · Cited by 189
The role of JNK in the development of hepatocellular carcinoma
Das, M., Garlick, D. S., Greiner, D. L., & Davis, R. J. (2011) · Genes & Development · doi:10.1101/gad.1989311 · Cited by 186
Targeting the ERK Signaling Pathway in Melanoma
Savoia, P., Fava, P., Casoni, F., & Cremona, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061483 · Cited by 184
Principles and mechanisms of non-genetic resistance in cancer
Bell, C. C., & Gilan, O. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0648-6 · Cited by 182
Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
Baenke, F., Chaneton, B., Smith, M., Van Den Broek, N., Hogan, K., Tang, H., Viros, A., Martin, M., Galbraith, L., Girotti, M. R., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.08.003 · Cited by 181
Keller, K. E., Doctor, Z. M., Dwyer, Z. W., & Lee, Y.-S. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.02.015 · Cited by 179
NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development
Ratnam, N. M., Peterson, J. M., Talbert, E. E., Ladner, K. J., Rajasekera, P. V., Schmidt, C. R., Dillhoff, M. E., Swanson, B. J., Haverick, E., Kladney, R. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91561 · Cited by 175
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Lu, H., Liu, S., Zhang, G., Wu, B., Zhu, Y., Frederick, D. T., Hu, Y., Zhong, W., Randell, S., Sadek, N., et al. (2017) · Nature · doi:10.1038/nature24040 · Cited by 169
Computational Approaches for Analyzing Information Flow in Biological Networks
Kholodenko, B., Yaffe, M. B., & Kolch, W. (2012) · Science Signaling · doi:10.1126/scisignal.2002961 · Cited by 168
Self-citationIRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
Wee, Z. N., Yatim, S. M. J. M., Kohlbauer, V. K., Feng, M., Goh, J. Y., Bao, Y., Lee, P. L., Zhang, S., Wang, P. P., Lim, E., et al. (2015) · Nature Communications · doi:10.1038/ncomms9746 · Cited by 168
Serine and Functional Metabolites in Cancer
Newman, A. C., & Maddocks, O. D. K. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.05.001 · Cited by 167
The 2 Faces of JNK Signaling in Cancer
Tournier, C. (2013) · Genes & Cancer · doi:10.1177/1947601913486349 · Cited by 165
Urosevic, J., García‐Albéniz, X., Planet, E., Real, S., Céspedes, M. V., Guiu, M., Fernández, E., Bellmunt, A., Gawrzak, S., Pavlović, M., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2977 · Cited by 163
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 160
BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
Sanchez, J., Wang, T., & Cohen, M. S. (2018) · Drugs · doi:10.1007/s40265-018-0884-8 · Cited by 155
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms
Wu, P., & Park, J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.023 · Cited by 147
Targeting the unfolded protein response in cancer
Ojha, R., & Amaravadi, R. K. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.003 · Cited by 146
Roles of p38 MAPKs in invasion and metastasis
Barrantes, I. D. B., & Nebreda, Á. R. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110676 · Cited by 144
Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening
Nguyen, T. V., Sleiman, M., Moriarty, T., Herrick, W. G., & Peyton, S. R. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.058 · Cited by 143
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 143
Yang, P., Su, C., Luo, X., Zeng, H., Zhao, L., Wei, L., Zhang, X., Varghese, Z., Moorhead, J., Chen, Y.-X., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.006 · Cited by 138
Trowe, T., Boukouvala, S., Calkins, K., Cutler, R. E., Fong, R., Funke, R. P., Gendreau, S. B., Kim, Y. D., Miller, N., Woolfrey, J. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4367 · Cited by 136
Yokota, T., & Wang, Y. (2016) · Gene · doi:10.1016/j.gene.2015.09.030 · Cited by 127
Zheng, X., Vis, D. J., Bruna, A., Šuštić, T., van Wageningen, S., Batra, A. S., Rueda, O. M., Bosdriesz, E., Caldas, C., Wessels, L. F. A., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0044-4 · Cited by 126
Insua‐Rodríguez, J., Pein, M., Hongu, T., Meier, J., Descot, A., Lowy, C., Braekeleer, E. D., Sinn, H., Spaich, S., Sütterlin, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809003 · Cited by 123
A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma
Guo, G., Gong, K., Ali, S., Ali, N., Shallwani, S., Hatanpaa, K. J., Pan, E., Mickey, B., Burma, S., Wang, D. H., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4584 · Cited by 121
Cesi, G., Walbrecq, G., Zimmer, A. D., Kreis, S., & Haan, C. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0667-y · Cited by 115
Hegde, P. S., Rusnak, D. W., Bertiaux, M., Alligood, K. J., Strum, J. C., Gagnon, R., & Gilmer, T. M. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0399 · Cited by 114
Chen, S.-F., Nieh, S., Jao, S., Liu, C., Wu, C.-H., Chang, Y., Yang, C., & Lin, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049275 · Cited by 113
Patnaik, S., & Anupriya, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00588 · Cited by 112
Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
Wang, J., Huang, S. K., Marzese, D. M., Hsu, S. C., Kawas, N. P., Chong, K. K., Long, G. V., Menzies, A. M., Scolyer, R. A., Izraely, S., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.418 · Cited by 110
CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors
Saygin, C., Wiechert, A. C., Rao, V. S., Alluri, R. K., Connor, E. V., Thiagarajan, P. S., Hale, J. S., Li, Y., Chumakova, A. P., Jarrar, A., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20170438 · Cited by 110
Nicke, B., Bastien, J., Khanna, S. J., Warne, P. H., Cowling, V., Cook, S. J., Peters, G., Delpuech, O., Schulze, A., Berns, K., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.038 · Cited by 108
Wu, X., Zhang, W., Font-Burgada, J., Palmer, T. D., Hamil, A. S., Biswas, S. K., Poidinger, M., Borcherding, N. C., Xie, Q. M., Ellies, L. G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414358111 · Cited by 107
Aesöy, R., Sanchez, B. C., Norum, J. H., Lewensohn, R., Viktorsson, K., & Linderholm, B. K. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2172 · Cited by 105
Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation
Haq, R., Fisher, D. E., & Widlund, H. R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0898 · Cited by 105
Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer
Eritja, N., Chen, B., Barrueco, R. R., Santacana, M., Gatius, S., Vidal, A., Martí, M. D., Ponce, J., Bergadà, L., Yeramian, A., et al. (2017) · Autophagy · doi:10.1080/15548627.2016.1271512 · Cited by 104
Feng, X., Liu, H., Zhang, Z., Gu, Y., Qiu, H., & He, Z. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0594-1 · Cited by 103
Notte, A., Ninane, N., Arnould, T., & Michiels, C. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.167 · Cited by 102
Ross, K. C., Andrews, A. J., Marion, C. D., Yen, T. J., & Bhattacharjee, V. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0798 · Cited by 102
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression
Schramek, D., Kotsinas, A., Meixner, A., Wada, T., Elling, U., Pospisilik, J. A., Neely, G. G., Zwick, R. H., Sigl, V., Forni, G., et al. (2011) · Nature Genetics · doi:10.1038/ng.767 · Cited by 101
Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
Jin, X., Pan, Y., Wang, L., Ma, T., Zhang, L., Tang, A., Billadeau, D. D., Wu, H., & Huang, H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3143 · Cited by 98
c-Jun NH2-Terminal Kinase 1 Is a Critical Regulator for the Development of Gastric Cancer in Mice
Shibata, W., Maeda, S., Hikiba, Y., Yanai, A., Sakamoto, K., Nakagawa, H., Ogura, K., Karin, M., & Omata, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6332 · Cited by 97
Strub, T., Ghiraldini, F. G., Carcamo, S., Li, M., Wroblewska, A., Singh, R., Goldberg, M. S., Hasson, D., Wang, Z., Gallagher, S. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05966-z · Cited by 97
Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
Echevarría-Vargas, I. M., Reyes-Uribe, P. I., Guterres, A. N., Yin, X., Kossenkov, A. V., Liu, Q., Zhang, G., Krepler, C., Cheng, C., Wei, Z., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708446 · Cited by 96
Maertens, O., Kuzmickas, R., Manchester, H. E., Emerson, C. E., Gavin, A. G., Guild, C. J., Wong, T. C., De Raedt, T., Bowman-Colin, C., Hatchi, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0879 · Cited by 95
Paranjape, A. N., Soundararajan, R., Werden, S. J., Joseph, R., Taube, J. H., Liu, H., Rodriguez‐Canales, J., Sphyris, N., Wistuba, I. I., Miura, N., et al. (2016) · Oncogene · doi:10.1038/onc.2015.498 · Cited by 93
Li, S.-P., Junttila, M. R., Han, J., Kähäri, V., & Westermarck, J. K. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3320 · Cited by 89
The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer
Ma, Y., Wang, L., Neitzel, L. R., Loganathan, S. N., Tang, N., Qin, L., Crispi, E. E., Guo, Y. P., Knapp, S., Beauchamp, R. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0453 · Cited by 78
Ozawa, H., Ranaweera, R. S., Izumchenko, E., Makarev, E., Zhavoronkov, A. A., Fertig, E. J., Howard, J. D., Marković, A. K., Bedi, A., Ravi, R. K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1686 · Cited by 78
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies
Rizzolio, S., Cagnoni, G., Battistini, C., Bonelli, S., Isella, C., Ginderachter, J. A. V., Bernards, R., Nicolantonio, F. D., Giordano, S., & Tamagnone, L. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99257 · Cited by 78
Sato, H., Yamamoto, H., Sakaguchi, M., Shien, K., Tomida, S., Shien, T., Ikeda, H., Hatono, M., Torigoe, H., Namba, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13763 · Cited by 78
Carson, R., Çeltikçi, B., Fenning, C., Javadi, A., Crawford, N., Pérez–Carbonell, L., Lawler, M., Longley, D. B., Johnston, P. G., & Schaeybroeck, S. V. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2701 · Cited by 77
Parmar, S., Katsoulidis, E., Verma, A. K., Li, Y., Sassano, A., Lal, L., Majchrzak, B., Ravandi, F., Tallman, M. S., Fish, E. N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400590200 · Cited by 77
Amoedo, N. D., Obre, E., & Rossignol, R. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.02.005 · Cited by 76
Integrating network reconstruction with mechanistic modeling to predict cancer therapies
Halász, M., Kholodenko, B. Ν., Kölch, W., & Santra, T. (2016) · Science Signaling · doi:10.1126/scisignal.aae0535 · Cited by 75
Distinct histone modifications denote early stress-induced drug tolerance in cancer
Emran, A. A., Marzese, D. M., Menon, D. R., Stark, M. S., Torrano, J., Hammerlindl, H., Zhang, G., Brafford, P. A., Salomon, M. P., Nelson, N. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23654 · Cited by 75
Muranen, T. E., Selfors, L. M., Hwang, J., Gallegos, L. L., Coloff, J. L., Thoreen, C. C., Kang, S. A., Sabatini, D. M., Mills, G. B., & Brugge, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0155 · Cited by 74
HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
Emmons, M. F., Faião-Flores, F., Sharma, R., Thapa, R., Messina, J. L., Becker, J. C., Schadendorf, D., Seto, E., Sondak, V. K., Koomen, J. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0040 · Cited by 73
Okada, M., Shibuya, K., Satō, A., Seino, S., Suzuki, S., Seino, M., & Kitanaka, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2087 · Cited by 72
Rukhlenko, O. S., Khorsand, F., Krstić, A., Rožanc, J., Alexopoulos, L. G., Rauch, N., Erickson, K. E., Hlavacek, W. S., Posner, R. G., Gómez‐Coca, S., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.002 · Cited by 72
Self-citationLiu, Y., Zhang, J., Sun, X., Su, Q., & You, C. (2017) · Oncotarget · doi:10.18632/oncotarget.17136 · Cited by 69
Qi, X.-M., Tang, J., Pramanik, R., Schultz, R. M., Shirasawa, S., Sasazuki, T., Han, J., & Chen, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313964200 · Cited by 68
Mishra, R. R., Belder, N., Ansari, S. A., Kayhan, M., Bal, H., Raza, U., Ersan, P. G., Tokat, Ü. M., Eyüpoğlu, E., Saatci, Ö., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2776 · Cited by 68
Milone, M. R., Pucci, B., Bruzzese, F., Carbone, C., Piro, G., Costantini, S., Capone, F., Leone, A., Gennaro, E. D., Caraglia, M., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.165 · Cited by 65
Gonçalves-Ribeiro, S., Díaz-Maroto, N. G., Berdiel‐Acer, M., Soriano, A., Guardiola, J., Martinez–Villacampa, M., Salazar, R., Capellá, G., Villanueva, A., Martinez‐Balibrea, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11121 · Cited by 63
P38 MAPK Contributes to Resistance and Invasiveness of HER2- Overexpressing Breast Cancer
Donnelly, S.-M., Paplomata, E., Peake, B. M., Sanabria, E., Chen, Z., & Nahta, R. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867320666131119155023 · Cited by 61
RANK expression on breast cancer cells promotes skeletal metastasis
Blake, M., Tometsko, M. E., Miller, R. E., Jones, J. C., & Dougall, W. C. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9624-3 · Cited by 60
IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance
YE, X.-L., Zhao, Y., Weng, G., Chen, Y., Wei, X., Shao, J., & Ji, H. (2015) · Oncology Reports · doi:10.3892/or.2015.3898 · Cited by 60
Lee, M. H., Lee, S. E., Kim, D. W., Ryu, M. J., Kim, S. J., Kim, S. J., Kim, Y. K., Park, J. H., Kweon, G. R., Kim, J., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1071 · Cited by 59
Self-citationTherapeutic control and resistance of the EGFR-driven signaling network in glioblastoma
Azuaje, F. J., Tiemann, K., & Niclou, S. P. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0098-6 · Cited by 56
Brady, S. W., Zhang, J., Tsai, M.-H., & Yu, D. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2014.1002693 · Cited by 56
Hardeman, K. N., Peng, C., Paudel, B. B., Meyer, C. T., Luong, T., Tyson, D. R., Young, J. D., Quaranta, V., & Fessel, J. P. (2017) · Scientific Reports · doi:10.1038/srep42604 · Cited by 54
Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
Wahid, M., Jawed, A., Mandal, R. K., Dar, S. A., Akhter, N., Somvanshi, P., Khan, F., Lohani, M., Areeshi, M. Y., & Haque, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.005 · Cited by 54
Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism.
Mazurek, S., Drexler, H. C. A., Troppmair, J., EIGENBRODT, E., & Rapp, U. R. (2007) · PubMed · Cited by 53
Interfering with MAP Kinase Docking Interactions: Implications and Perspectives for the p38 Route
Mayor, F., Jurado-Pueyo, M., Campos, P. M., & Murga, C. (2007) · Cell Cycle · doi:10.4161/cc.6.5.3920 · Cited by 53
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
Wetterskog, D., Shiu, K.-K., Chong, I. Y.-S., Meijer, T. G., Mackay, A. G., Lambros, M. B. K., Cunningham, D., Reis-Filho, J. S., Lord, C. J., & Ashworth, A. (2013) · Oncogene · doi:10.1038/onc.2013.41 · Cited by 52
Chao, M., Chang, L.-H., Tu, H., Chang, C.-D., Lai, M.-J., Chen, Y.-Y., Liou, J., Teng, C., & Pan, S. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0681-6 · Cited by 52
Kosinsky, R. L., Helms, M., Zerche, M., Wohn, L., Dyas, A., Prokakis, E., Kazerouni, Z. B., Bedi, U., Wegwitz, F., & Johnsen, S. A. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2141-9 · Cited by 51
Park, S., Seong, M. A., & Lee, H. (2016) · Oncotarget · doi:10.18632/oncotarget.6945 · Cited by 50
Targeting FBPase is an emerging novel approach for cancer therapy
Liu, G., & Zhang, Y.-M. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0533-z · Cited by 50
Kholodenko, B. N. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.014 · Cited by 49
Xie, H., Li, C., Dang, Q., Chang, L. S., & Li, L. (2016) · Oncotarget · doi:10.18632/oncotarget.6372 · Cited by 49
Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib
Dumka, D., Puri, P., Carayol, N., Lumby, C., Balachandran, H., Schuster, K., Verma, A. K., Terada, L. S., Platanias, L. C., & Parmar, S. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903147637 · Cited by 49
Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation
Jambrina, P. G., Rauch, N., Pilkington, R., Rybakova, K. N., Nguyen, L. K., Kholodenko, B. Ν., Buchete, N., Kölch, W., & Rosta, E. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201509272 · Cited by 49
MEK inhibitors in oncology: a patent review (2015-Present)
Mahapatra, D. K., Asati, V., & Bharti, S. K. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1339688 · Cited by 48
Gupta, R., Bugide, S., Wang, B., Green, M. R., Johnson, D. B., & Wajapeyee, N. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821889116 · Cited by 47
BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
Paoluzzi, L., Hanniford, D., Sokolova, E., Osman, I., Darvishian, F., Wang, J., Bradner, J. E., & Hernando, E. (2016) · Cancer Medicine · doi:10.1002/cam4.667 · Cited by 45
Girnius, N., Edwards, Y. J. K., Garlick, D. S., & Davis, R. J. (2018) · eLife · doi:10.7554/elife.36389 · Cited by 45
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Khaliq, M., & Fallahi‐Sichani, M. (2019) · Cancers · doi:10.3390/cancers11101480 · Cited by 43
Šuštić, T., van Wageningen, S., Bosdriesz, E., Reid, R. J. D., Dittmar, J., Lieftink, C., Beijersbergen, R. L., Wessels, L. F. A., Rothstein, R., & Bernards, R. (2018) · Genome Medicine · doi:10.1186/s13073-018-0600-z · Cited by 42
Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
Li, G., Wang, X., Hibshoosh, H. H., Jin, C., & Halmos, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106349 · Cited by 41
The Mitogen-Activated Protein Kinase Kinase 4 Has a Pro-Oncogenic Role in Skin Cancer
Finegan, K. G., & Tournier, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3669 · Cited by 41
Role of the unfolded protein response in tumor cell characteristics and cancer outcome
Galmiche, A., Sauzay, C., Chevet, É., & Pluquet, O. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000339 · Cited by 41
Wang, Q., Shi, S., He, W., Padilla, M. T., Zhang, L., Wang, X., Zhang, B., & Lin, Y. (2014) · Oncotarget · doi:10.18632/oncotarget.1798 · Cited by 40
Yeung, Y. T., Yin, S., Lu, B., Fan, S., Yang, R., Bai, R., Zhang, C., Bode, A. M., Liu, K., & Dong, Z. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.017 · Cited by 40
Roy, S., Roy, S., Kar, M., Padhi, S., Saha, A., Anuja, K., & Banerjee, B. (2018) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12707 · Cited by 39
ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression
Ma, Q., Wu, K., Li, H., Li, H., Zhu, Y., Hu, G., Hu, L., & Kong, X. (2019) · Scientific Reports · doi:10.1038/s41598-019-56277-2 · Cited by 38
Ji, H. L., Lü, H., Li, Y., LU, L., Wang, J., Zhang, Y., & SHANG, H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3867 · Cited by 37
Liu, C., Chen, S.-F., Wu, M.-Z., Jao, S., Lin, Y., Yang, C., Lee, T., Wen, L.-W., Lan, G., & Nieh, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7306 · Cited by 37
Basile, K. J., Abel, E. V., Dadpey, N., Hartsough, E. J., Fortina, P. M., & Aplin, A. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1628 · Cited by 35
Zhang, Y., Wang, X., Qin, X., Wang, X., Liu, F., White, E., & Zheng, X. F. S. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.031 · Cited by 33
Seino, M., Okada, M., Sakaki, H., TAKEDA, H., WATARAI, H., Suzuki, S., Seino, S., Kuramoto, K., Ohta, T., Nagase, S., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4377 · Cited by 29
Survivin is a guardian of the intestinal stem cell niche and its expression is regulated by TGF-β
Martini, E., Schneider, E., Neufert, C. F., Neurath, M. F., & Becker, C. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1231286 · Cited by 29
Faghfuri, E., Nikfar, S., Niaz, K., Faramarzi, M. A., & Abdollahi, M. R. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1432593 · Cited by 29
Vidula, N., Yau, C. S. F., Li, J., Esserman, L. J., & Rugo, H. S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4318-1 · Cited by 22
Zhao, T., Bai, J., Zou, Q., Chen, F., & Xie, Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7752 · Cited by 22
Rincón, R., Zazo, S., Chamizo, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0920 · Cited by 21
Id4 promotes cisplatin resistance in lung cancer through the p38 MAPK pathway
Kang, Q., Li, Y., Li, X., Lei, X., Wang, B., Zhang, L., & Chu, X. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000414 · Cited by 20
Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin
Lin, Y.-T., Liu, Y., & Chao, C. C. ‐. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.003 · Cited by 20
Cited by
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Natural Products as Anticancer Agents: Current Status and Future Perspectives
Naeem, A., Hu, P., Yang, M., Zhang, J., Liu, Y., Zhu, W., & Zheng, Q. (2022) · Molecules · doi:10.3390/molecules27238367 · Cited by 607
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Metadata
- Authors
- Lee, S., Rauch, J., & Kolch, W.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-02-07
- Volume
- 21
- Issue
- 3
- Pages
- 1102
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3005196658
- Cited by
- 799
- References
- 202
- FWCI
- 29.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.